<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; GERN</title>
	<atom:link href="http://www.stockbloghub.com/tag/gern/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GERN) Geron 2011 First Quarter Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2011/05/03/gern-geron-2011-first-quarter-posts-wider-loss/72990</link>
		<comments>http://www.stockbloghub.com/2011/05/03/gern-geron-2011-first-quarter-posts-wider-loss/72990#comments</comments>
		<pubDate>Tue, 03 May 2011 18:33:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72990</guid>
		<description><![CDATA[Geron Corporation (GERN) posted a net loss of 20 cents per share in the first quarter of 2011, wider than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 18 cents. First quarter revenues of $1.5 million were just above the Zacks Consensus Estimate of $1 million and higher than the year-ago revenues of $0.9 million. Higher expenses led to the wider first quarter loss. Quarter in Detail Revenues consisted of $150,000 in revenues from collaborative agreements and $1.4 million in the form of royalties and license fees. Geron has several license agreements with various oncology, diagnostics, research tools, agriculture and biologics production companies. Total operating expenses were $25.9 million, 48.7% above the $17.4 million reported in the year-ago period. Research and development expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/gern-geron-2011-first-quarter-posts-wider-loss/72990/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GERN) Geron&#8217;s Earnings Report Misses Expectations</title>
		<link>http://www.stockbloghub.com/2010/03/03/gern-gerons-earnings-report-misses-expectations/29577</link>
		<comments>http://www.stockbloghub.com/2010/03/03/gern-gerons-earnings-report-misses-expectations/29577#comments</comments>
		<pubDate>Wed, 03 Mar 2010 22:18:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29577</guid>
		<description><![CDATA[Geron Corporation (GERN) posted a net loss of $18.4 million, or 20 cents per share in the fourth quarter of 2009, higher than the Zacks Consensus Estimate of a loss of 17 cents. However, the result was better than the year-ago loss of 22 cents. For 2009, the company reported a loss per share of 80 cents compared to a loss of 79 cents in 2008. Revenues for the quarter increased 11.2% year-over-year to $605,000. Revenues consisted of $225,000 from collaborative agreements and $380,000 from royalties and license fees. Geron has several license agreements with various oncology, diagnostics, research tools, and agriculture and biologics production companies. Collaborative revenues for 2009 reflect revenues recognized under the company’s collaboration with GE Healthcare Ltd. For the full year, Geron’s revenues came in at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/gern-gerons-earnings-report-misses-expectations/29577/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GERN) Geron&#8217;s GRNVAC1 Vaccine Shows Promise</title>
		<link>http://www.stockbloghub.com/2009/12/11/gern-gerons-grnvac1-vaccine-shows-promise/22627</link>
		<comments>http://www.stockbloghub.com/2009/12/11/gern-gerons-grnvac1-vaccine-shows-promise/22627#comments</comments>
		<pubDate>Fri, 11 Dec 2009 23:01:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22627</guid>
		<description><![CDATA[Biotech company Geron (GERN) recently presented encouraging interim data on its pipeline candidate, GRNVAC1, at the annual meeting of the American Society of Hematology (ASH). GRNVAC1 is a vaccine, which is being developed to help extend the remission of acute myelogenous leukemia (AML). Data from the multi-center, open-label phase II study showed that the candidate achieved its endpoints of safety and tolerability. The trial has been designed to study the safety and tolerability of the vaccination regimen in patients with AML who are in complete clinical remission. Additional objectives include the evaluation of immune responses to GRNVAC1 and to explore the effects of vaccination on minimal residual disease and relapse rates in this patient population. Interim data showed that 14 out of 20 patients in the study remain in complete ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/gern-gerons-grnvac1-vaccine-shows-promise/22627/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GERN) Geron FDA Experimental Application on Hold</title>
		<link>http://www.stockbloghub.com/2009/08/28/gern-geron-fda-experimental-application-on-hold/13824</link>
		<comments>http://www.stockbloghub.com/2009/08/28/gern-geron-fda-experimental-application-on-hold/13824#comments</comments>
		<pubDate>Sat, 29 Aug 2009 00:15:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13824</guid>
		<description><![CDATA[Yesterday, Geron Corp. (GERN) provided an update on its experimental candidate, GRNOPC1, which is currently under clinical hold. On Aug. 18, Geron suffered a setback when the US Food and Drug Administration (FDA) put its Investigational New Drug (IND) application for the product on hold. Earlier this year, the FDA cleared the company to begin clinical trials of GRNOPC1 for acute spinal cord injury. However, later the agency placed the trial on hold pending a review of new non-clinical animal study data submitted by the company. Yesterday, Geron announced that the human study is being delayed as some animals treated with the injection developed microscopic spinal cysts in the regenerating injury site. It said that the cysts were non-proliferative, confined to the injury site and had no adverse effect on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/gern-geron-fda-experimental-application-on-hold/13824/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GERN) Geron Corporation: Stock of the Day</title>
		<link>http://www.stockbloghub.com/2009/01/29/geron-corporation-stock-of-the-day/2398</link>
		<comments>http://www.stockbloghub.com/2009/01/29/geron-corporation-stock-of-the-day/2398#comments</comments>
		<pubDate>Fri, 30 Jan 2009 00:01:55 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2398</guid>
		<description><![CDATA[by Katharine Schildt, Assistant Editor, The Oxford Club A New Era for Stem Cell Research Stem cell research has been a controversial subject for quite some time. And it’s been no secret that the Bush administration wasn’t a big fan. But just days after President Obama’s inauguration, a huge breakthrough has already been made in the administrative logjam. Obama officially relaxed the restrictions on federal funding of stem cell research, which has sent shares of this biopharmaceutical company soaring. Geron Corp. (Nasdaq: GERN), based in the United States, is the premiere developer of biopharmaceuticals for the treatment of certain cancers, as well as degenerative diseases such as spinal cord injury and diabetes. Already a global leader in the development of embryonic stem cell-based therapies, the U.S. Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/29/geron-corporation-stock-of-the-day/2398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

